Biotech Values

[DewDiligence]

GILD 3Q20 HCV sales=$464M, +4% QoQ, -31% YoY. The 3Q20 geographic breakdown was: US $241M; EU $98M; RoW $125M.

During 3Q20, COVID-19 continued to impede new-patient starts for HCV treatment in all geographies (CC slide #52, see link below). GILD’s worldwide HCV patient starts in 3Q20 (CC slide #21, see link below) were 31K, up from 25K in 2Q20, but down from 45K in 1Q20 (pre-pandemic). 21K of the 31K patient starts in 3Q20 were in the US.

PR:
https://www.gilead.com/news-and-press/press-room/press-releases/2020/10/gilead-sciences-announces-third-quarter-2020-financial-results

CC slides:
http://investors.gilead.com/static-files/7db4987f-930d-4b18-877e-0c75d5e34c0d